Iradimed CorpIRMD
Price$85.30Intrinsic value$70.3718% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $86.3M+17.9% YoYTTM through 30 Jun 2026
Net Income $23.1M+19.9% YoYTTM through 30 Jun 2026
Free Cash Flow $25.1MTTM through 30 Jun 2026

Margins

Current
Gross Margin77.0%
EBITDA Margin33.8%
Operating Margin31.2%
Net Margin26.7%

Returns

23.8%ROE
20.7%ROA
23.8%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.98x
Net Debt-$51.2Mnet cash position
Cash & Equivalents$59.1M

Quality Metrics

Altman Z-Score53.38
Piotroski F-Score6 / 9
FCF Margin29.1%
Rule of 4034.7
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $83.8M
Diluted EPS$1.79TTM
'19'20'21'22'23'24'25
FY2025: $1.75

Dividend

$0.90Per share, FY20261.04%Yield2 yrsStreak

Capital Allocation

R&D Spend$3.1M
Capex Intensity2.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.